Phase 1 N=24 Effect of, OAT3, on the Renal Secretion of Cefotaxime
Focus Groups
Primary: Effect of OAT3 on Renal Secretion of Cefotaxime IV Based on Genotype — 84.8; 158 mL/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=50 Motivational Interviewing to Improve Medication Adherence Among Hispanic Adults With Depression
Depression
Primary: Medication Adherence, as Measured by Electronic Pill Container — 58.76; 34.7 Percentage of Days — p=<.05
Phase 1 N=85 A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.
HIV Infections
Primary: Trough Cpre,N. — 15.47; 16.66 (ng/mL/mg) — p=0.0080
Phase 1 N=48 Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor
Healthy
Primary: Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss) — 551; 817; 689; 660 ng*h/mL — p=0.9456
Phase 1 N=27 A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
Metastatic Pancreatic Cancer
Primary: Toxicity (Number of Patients Who Experiened DLTs) — 0; 1; 1; 2 participants
Phase 1 N=63 A Trial to Investigate the Relative Efficacy, Safety, and Tolerability of Octaplas LG Versus Octaplas SD
Comparison of Octaplas LG and Octaplas SD
Primary: Recovery of the Coagulation Factors I, II, V, VII, VIII, IX, X, and XI — 8.11; 9.12; 7.08; 6.68 Percentage change
Phase 1 N=32 Relative Bioavailability of of Olodaterol and Ketoconazole
Healthy · Pulmonary Disease, Chronic Obstructive
Primary: Area Under Curve From 0 to 1 Hour at Steady State (AUC0-1,ss) — 2.512; 4.231 Picogram*hours/milliliter — p=1.0000
Phase 1 N=117 A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject
Healthy
Primary: Skin Irritation Score of the Application Site — 0.237; 0.289; 0.250 Scores on a scale
Phase 1 N=89 Assessment of Arachidonic Acid Supplementation in Infant Formula on the Immune Response of Infants
Focus: Nutritional Requirements for Infants
Primary: Number of Antigen-presenting B Cells — 21.9; 22.8; 25.1 percentage of CD20+ B cells
Phase 1 N=21 Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy
Hormone-refractory Prostate Cancer
Primary: Adverse Events — 67; 8; 9; 0 Events
Phase 1 N=13 Phase I Study to Investigate the Effect on the Blood Pressure After Oral Administration of SK3530 and Amlodipine
Hypertension
Primary: Maximal Change From Baseline in Standing SBP — -7.42; -4.42 mmHg
Phase 1 N=30 Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers
Healthy Volunteers
Primary: Area Under the Plasma Concentration-time Curve (AUC) for Lisdexamfetamine Dimesylate — 27.0; 36.0; 38.3 ng*hr/ml
Phase 1 N=40 Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants Reporting Serious Adverse Events and Grade 3 Adverse Reactions Following a Single Booster Dose of Adacel™ Vaccine — 0; 0; 0; 3 Participants
Phase 1 N=62 Safety Tolerability and Pharmacokinetic of BI 411034
Healthy
Primary: Number of Participants With Drug Related AEs — 1; 0; 0; 1 participants
Phase 1 N=55 Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2
Neoplasms
Primary: Number of Participants With Dose-limiting Toxicities (DLT) — 0; 1; 4; 0 participants